| [1] |
Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin， 2021， 71(3)：209-249.DOI： 10.3322/caac.21660.
|
| [2] |
Parker C, Castro E, Fizazi K, et al.Prostate cancer：ESMO clinical practice guidelines for diagnosis，treatment and follow-up[J]. Ann Oncol， 2020， 31(9)：1119-1134.DOI： 10.1016/j.annonc.2020.06.011.
|
| [3] |
Cornford P, van den Bergh R, Briers E, et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer.Part II-2020 update：treatment of relapsing and metastatic prostate cancer[J]. Eur Urol， 2021， 79(2)：263-282.DOI： 10.1016/j.eururo.2020.09.046.
|
| [4] |
|
| [5] |
Nuhn P, De Bono JS, Fizazi K, et al.Update on systemic prostate cancer therapies：management of metastatic castration-resistant prostate cancer in the era of precision oncology[J]. Eur Urol， 2019， 75(1)：88-99.DOI： 10.1016/j.eururo.2018.03.028.
|
| [6] |
|
| [7] |
Farhangnia P, Ghomi SM, Akbarpour M, et al.Bispecific antibodies targeting CTLA-4：game-changer troopers in cancer immunotherapy[J]. Front Immunol， 2023(14)：1155778.DOI： 10.3389/fimmu.2023.1155778.
|
| [8] |
Isaacsson Velho P, Antonarakis ES.PD-1/PD-L1 pathway inhibitors in advanced prostate cancer[J]. Expert Rev Clin Pharmacol， 2018， 11(5)：475-486.DOI： 10.1080/17512433.2018.1464388.
|
| [9] |
Xu Y, Song G, Xie S, et al. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer[J]. Mol Ther， 2021， 29(6)：1958-1969.DOI： 10.1016/j.ymthe.2021.04.029.
|
| [10] |
Hossen MM, Ma Y, Yin Z, et al.Current understanding of CTLA-4：from mechanism to autoimmune diseases[J]. Front Immunol， 2023(14)：1198365.DOI： 10.3389/fimmu.2023.1198365.
|
| [11] |
Wei SC, Duffy CR, Allison JP.Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov， 2018， 8(9)：1069-1086.DOI： 10.1158/2159-8290.CD-18-0367.
|
| [12] |
Kwon J, Bryant RJ, Parkes EE.The tumor microenvironment and immune responses in prostate cancer patients[J]. Endocr Relat Cancer， 2021， 28(8)：T95-T107.DOI： 10.1530/ERC-21-0149.
|
| [13] |
Subudhi SK, Vence L, Zhao H, et al.Neoantigen responses，immune correlates，and favorable outcomes after ipilimumab treatment of patients with prostate cancer[J]. Sci Transl Med， 2020， 12(537)：eaaz3577 [pii].DOI： 10.1126/scitranslmed.aaz3577.
|
| [14] |
Kwon ED, Drake CG, Scher HI, et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043)：a multicentre，randomised，double-blind，phase 3 trial[J]. Lancet Oncol， 2014， 15(7)：700-712.DOI： 10.1016/S1470-2045(14)70189-5.
|
| [15] |
Fizazi K, Drake CG, Beer TM, et al.Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors[J]. Eur Urol， 2020， 78(6)：822-830.DOI： 10.1016/j.eururo.2020.07.032.
|
| [16] |
Beer TM, Logothetis C, Sharma P, et al.CA184-095：a randomized，double-blind，phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)[J]. J Clin Oncol， 2013， 31(1)：15-16.DOI： 10.1186/1477-7819-11-101.
|
| [17] |
Beer TM, Kwon ED, Drake CG, et al.Randomized，double-blind，phase Ⅲ trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer[J]. J Clin Oncol， 2017， 35(1)：40-47.DOI： 10.1200/JCO.2016.69.1584.
|
| [18] |
Jafari S, Molavi O, Kahroba H, et al.Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer[J]. Cell Mol Life Sci， 2020， 77(19)：3693-3710.DOI： 10.1007/s00018-020-03459-1.
|
| [19] |
Antonarakis ES, Piulats JM, Gross-Goupil M, et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer：multicohort，open-label phase Ⅱ KEYNOTE-199 study[J]. J Clin Oncol， 2020， 38(5)：395-405.DOI： 10.1200/JCO.19.01638.
|
| [20] |
Abida W, Cheng ML, Armenia J, et al.Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade[J]. JAMA Oncol， 2019， 5(4)：471-478.DOI： 10.1001/jamaoncol.2018.5801.
|
| [21] |
Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA[J]. J Immunother Cancer， 2020， 8(2)：e001065.DOI： 10.1136/jitc-2020-001065.
|
| [22] |
Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer：response to PD-1 blockade and standard therapies[J]. PLoS One， 2020， 15(5)：e0233260.DOI： 10.1371/journal.pone.0233260.
|
| [23] |
Hansen AR, Massard C, Ott PA, et al.Pembrolizumab for advanced prostate adenocarcinoma：findings of the KEYNOTE-028 study[J]. Ann Oncol， 2018， 29(8)：1807-1813.DOI： 10.1093/annonc/mdy232.
|
| [24] |
Petrylak DP, Loriot Y, Shaffer DR, et al.Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer：a phase i study[J]. Clin Cancer Res， 2021， 27(12)：3360-3369.DOI： 10.1158/1078-0432.CCR-20-1981.
|
| [25] |
Vitkin N, Nersesian S, Siemens DR, et al. The tumor immune contexture of prostate cancer[J]. Front Immunol， 2019(10)：603.DOI： 10.3389/fimmu.2019.00603.
|
| [26] |
Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer：preliminary analysis of patients in the checkmate 650 trial[J]. Cancer Cell， 2020， 38(4)：489-499.e3.DOI： 10.1016/j.ccell.2020.08.007.
|
| [27] |
Long X, Hou H, Wang X, et al.Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration[J]. Cell Death Dis， 2020， 11(9)：779.DOI： 10.1038/s41419-020-02973-1.
|
| [28] |
Graff JN, Antonarakis ES, Hoimes CJ, et al. Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)：KEYNOTE-199 cohorts 4-5[J]. J Clini Oncol， 2020， 38(6_suppl)：15.DOI： 10.1200/JCO.2020.38.6_suppl.15.
|
| [29] |
Graff JN, Beer TM, Alumkal JJ, et al.A phase Ⅱ single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone[J]. J Immunother Cancer， 2020， 8(2)：e000642.DOI： 10.1136/jitc-2020-000642.
|
| [30] |
Petrylak DP, Ratta R, Gafanov R, et al.KEYNOTE-921：phase Ⅲ study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer[J]. Future Oncol， 2021， 17(25)：3291-3299.DOI： 10.2217/fon-2020-1133.
|
| [31] |
Petrylak DP, Li B, Schloss C, et al.KEYNOTE-921：Phase Ⅲ study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)[J]. Ann Onco， 2019， 30(Supplement_5)：v351.DOI： 10.1093/annonc/mdz248.048.
|
| [32] |
Drake CG, Saad F, Clark WR, et al.690TiP a phase Ⅲ，randomized，double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX) - ScienceDirect[J]. Ann Oncol， 2020， 31(4)：S546.DOI： 10.1016/j.annonc.2020.08.2084.
|
| [33] |
Liu D．CAR-T " the living drugs" ，immune checkpoint inhibitors，and precision medicine：a new era of cancer therapy[J]. J Hematol Oncol， 2019， 12(1)：113.DOI： 10.1186/s13045-019-0819-1.
|
| [34] |
Sam J, Colombetti S, Fauti T, et al.Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity[J]. Front Oncol， 2020(10)：575737.DOI： 10.3389/fonc.2020.575737.
|
| [35] |
Daver N．A bispecific approach to improving CAR T cells in AML[J]. Blood， 2020， 135(10)：703-704.DOI： 10.1182/blood.2020004791.
|
| [36] |
Agarwal N, McGregor B, Maughan BL, et al.Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer：results from an expansion cohort of a multicentre，open-label，phase 1b trial (COSMIC-021)[J]. Lancet Oncol， 2022， 23(7)：899-909.DOI： 10.1016/S1470-2045(22)00278-9.
|
| [37] |
Cattrini C, España R, Mennitto A, et al.Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer[J]. Cancers (Basel)， 2021， 13(18)：4522.DOI： 10.3390/cancers13184522.
|